Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Background Recurrence rates of intrahepatic cholangiocarcinoma (iCCA) after curative
hepatectomy are as high as 50% to 70%, and about half of these recurrences occur within 2 …

Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver
malignancy after hepatocellular carcinoma. While surgical resection with negative margin is …

Importance Although surgery offers the best chance of a potential cure for patients with
localized, resectable intrahepatic cholangiocarcinoma (ICC), prognosis of patients remains …

Abstract 3D printing can produce intuitive, precise, and personalized anatomical models,
providing invaluable support for precision medicine, particularly in areas like surgical …

Background Upfront surgery is the current standard for resectable intrahepatic
cholangiocarcinoma (ICC) despite high treatment failure with this approach. We sought to …

TBX3 behaves as a tumor suppressor or oncoprotein across cancer. However, TBX3
function remains undetermined in intrahepatic cholangiocarcinoma (iCCA), a deadly primary …

Backgroud Resection is still the only potentially curative treatment for patients with
intrahepatic cholangiocarcinoma (ICC), but the prognosis remains far from satisfactory …

As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for
cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of< 10 …

Hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma
(CCA), and gallbladder carcinoma (GBC), are lethal cancers with limited therapeutic options …